Drugs & Targets FDA approves Degevma, a biosimilar for cancer-related bone complications October 02, 2026Vol.52 No.36
Drugs & Targets FDA approves Ponlimsi, a biosimilar for preventing fractures in prostate and breast cancer patients October 02, 2026Vol.52 No.36
Drugs & Targets FDA accepts NDA and grants Priority Review to Lynkuet for vasomotor symptoms due to endocrine therapy in breast cancer October 02, 2026Vol.52 No.36
News AnalysisRegulatory News FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claimsClinical benefit will not be considered for approval, FDA says September 25, 2026Vol.52 No.35By Jacquelyn Cobb and Sara Willa Ernst
Perspective When did stage 3B lung cancer become “early stage”? September 25, 2026Vol.52 No.35By Raja M. Flores
Cancer Policy At confirmation hearing, Heidi Overton sidesteps questions about FDA regulation of fruit-flavored vapes September 25, 2026Vol.52 No.35By Sara Willa Ernst
Cancer Policy HHS issues direct final rule to reduce reliance on animal testing September 25, 2026Vol.52 No.35By Claire Marie Porter
Drugs & Targets FDA approves Lyrfigtu for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma September 25, 2026Vol.52 No.35
Drugs & Targets FDA approves belzutifan in combination with lenvatinib for advanced RCC with a clear cell component September 25, 2026Vol.52 No.35
